Neovasc’s Refractory Angina Treatment Receives CE Mark

Results of a published prospective three-year clinical study have demonstrated that the Reducer is safe and effective at providing relief of angina symptoms in refractory angina patients.

Read more »

Neovasc Aims For CE Mark in 2012

OneMedRadio interviewed Alexei Marko, CEO and Director of Neovasc [CVE:NVC] where he discussed the company’s products for treating heart disease. The company’s flagship product The Reducer is in late stage development.

Read more »

More Than A Band-Aid For A Broken Heart: New Technology May Regenerate Failing Heart Tissue

For patients who have survived a heart attack, things get worse before they get better if they get better at all. Nearly 2 million people worldwide suffer from permanent heart damage due to lack of an appropriate therapy after a heart attack.

Read more »